About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- Iran becomes latest rogue state to develop its own cryptocurrency
- What the tax pros say you should do before heading their way
- 6 places you can ski, ice skate and luge on actual Olympic tracks
- Florida eye doctor linked to Sen. Bob Menendez gets 17 years for Medicare fraud
- Complaints about nursing home evictions rise, and regulators take note
NBR on TwitterMy Tweets
Subscribe to RSS
Biotech & Pharmaceuticals
Celgene agrees to buy biotechnology company Juno Therapeutics for about $9 billion.
Sixty-four percent of patients achieved major depressive disorder remission using SAGE-217 in the 15th day of treatment, Sage says.
Inter partes review is at the center of a case before the Supreme Court, and the decision will have far-reaching effects.
The approvals “mark another significant milestone for our company,” Mylan CEO Heather Bresch says.
Arena Pharmaceuticals’ drug Ralienpag met its Phase 2 program goals.
Lilly says the FDA needed additional data to “characterize safety concerns across treatment arms.”
While the White House and Congress struggled to repeal Obamacare, investors did not shy away from health-care stocks in the first quarter.
Drug maker Mylan said it was recalling select lots of the company’s EpiPen device due to a potential defect.
United Therapeutics said it would be delaying the launch of an implantable pump until 2018.
The track record in drug development for Alzheimer’s disease has been terrible: a success rate of less than 1 percent.
Almost 200,000 people have fatally overdosed on opioids in the past 15 years, with more than 30,000 people dying in 2015 alone.
Traders are worried that Repatha isn’t effective enough to justify the drug’s hefty price tag of over $14,500 per year.
The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer.
Express Scripts said despite the double-digit increase, costs for employers rose just 2.5 percent across all prescription drugs.
More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.